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SUMMARY. Aim.A wide range of clinical phenomena have been reported with dose reduction or drug discontinuation of Selective Serotonin Re-
uptake Inhibitors (SSRIs) or Serotonin Norepinephrine Reuptake Inhibitors (SNRIs). In 2015, a new classification of SSRIs/SNRIs withdrawal
(i.e., new withdrawal symptoms, rebound symptoms withdrawal, persistent post-withdrawal disorders) was outlined on the basis of the literature
and clinical observations. A semistructured clinical interview, the Diagnostic clinical Interview for Drug Withdrawal 1 - New Symptoms of SSRI
and SNRI (DID-W1), was developed for identifying and differentiating such syndromes. Its inter-rater reliability has been tested. Methods. Sev-
enteen consecutive outpatients with a history of SSRI or SNRI dose reduction or discontinuation were assessed independently by 2 clinicians at
different times during the same day. Percent agreement, Cohen’s kappa, and the squared correlation coefficient were used to measure inter-rater
reliability. Results.The percent agreement for the whole interview was 97.06%, the Cohen’s kappa 0.85 (95% CI of 0.61-1.08), the squared cor-
relation coefficient 0.72. Discussion and conclusions.The kappa values indicated excellent inter-rater agreement. Validity evaluation and com-
parison with other instruments need to be performed. The DID-W1 may help diagnosing the clinical phenomena related to SSRI and SNRI dis-
continuation, their differentiation from relapse, and the potential iatrogenic origin of psychiatric symptoms in clinical practice.
KEY WORDS: withdrawal, selective serotonin reuptake inhibitor, serotonin norepinephrine reuptake inhibitor, interview, reliability, iatro-
genic comorbidity.
RIASSUNTO. Scopo. Dopo la riduzione della dose o la sospensione di Selective Serotonin Reuptake Inhibitors (SSRI) o di Serotonin Nore-
pinephrine Reuptake Inhibitors (SNRI) si possono verificare molti fenomeni clinici. Nel 2015, è stata delineata una nuova classificazione delle
sindromi d’astinenza da SSRI/SNRI (cioè, nuovi sintomi, rimbalzo, disturbi persistenti post-astinenza) sulla base della letteratura e delle osser-
vazioni cliniche. Un’intervista clinica semistrutturata, la Diagnostic clinical Interview for Drug Withdrawal 1 - New Symptoms of SSRI and SNRI
(DID-W1), è stata sviluppata allo scopo di identificare e differenziare queste sindromi. La sua affidabilità fra valutatori è stata testata. Metodi.
Diciassette pazienti ambulatoriali consecutivi con una storia di riduzione o sospensione di SSRI o SNRI sono stati valutati indipendentemente
da 2 clinici in tempi diversi dello stesso giorno. La percentuale di accordo, il kappa di Cohen e il quadrato del coefficiente di correlazione sono
stati utilizzati per misurare l’affidabilità fra i valutatori. Risultati. La percentuale di accordo fra i valutatori relativamente all’intera intervista è
risultata pari al 97,06%, il kappa di Cohen è risultato pari allo 0,85 (IC95% di 0,61-1,08), il quadrato del coefficiente di correlazione è risultato
pari allo 0,72. Discussione e conclusioni. I valori di kappa indicano un eccellente accordo fra i valutatori. Sono opportune ulteriori indagini
sulla validità e confronti con altri strumenti. La DID-W1 può aiutare a diagnosticare i fenomeni clinici collegati alla sospensione di SSRI e SNRI,
a differenziarli dalla ricaduta e a identificare l’origine potenzialmente iatrogena dei sintomi psichiatrici nella pratica clinica.
PAROLE CHIAVE: astinenza, inibitori selettivi della ricaptazione della serotonina, inibitori della ricaptazione di serotonina e noradrenalina,
intervista, affidabilità, comorbilità iatrogena.
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INTRODUCTION
In 1968, Di Mascio and Shader introduced the concept of
behavioral toxicity of psychotropic medications which re-
ferred to the pharmacologic actions of a drug that, within the
range in which it has been found to possess clinical utility,
may produce alterations in mood, perceptual, cognitive, and
psychomotor functions that limit the capacity of the individ-
ual or constitute a hazard to well-being1-3. In 1980, Perl and
co-authors reviewed this concept discussing the mechanisms
by which psychotropic drugs can cause adverse reactions,
that is through the extension of their primary therapeutic ac-
tion and/or the onset of secondary actions as well as with-
drawal, dependence, and tolerance symptoms4. The concept
of drug-induced illness was reported by Chouinard et al.5,6
during antipsychotic withdrawal or switch, using the model
of neuroleptic-induced tardive dyskinesia with the sub-types
of withdrawal, overt, masked, and persistent7. The same con-
cepts were applied to antidepressant withdrawal8,9 and Fava
et al.10 defined a form of behavioral toxicity as iatrogenic co-
morbidity providing differentiation between adverse or
emergent events that are limited to the period of psy-
chotropic drug administration and effects that may persist
long after drug discontinuation10. They suggested that psy-
chotropic drug treatment, particularly after long-term use,
may increase the risk of experiencing additional psychologi-
cal problems or of modifying responsiveness to subsequent
treatments11.
There is a consistent body of knowledge that indicates
that dose reduction or discontinuation of Selective Serotonin
Reuptake Inhibitors (SSRI) or Serotonin Norepinephrine
Reuptake Inhibitors (SNRI) induces a number of clinical
phenomena (i.e., withdrawal or discontinuation syndromes,
rebound symptoms, persistent post-withdrawal disorders)
both in adults and in children12-20. There have been various
definitions17,21,22 as well as diagnostic criteria23,24 of these
clinical phenomena. In 2015, a comprehensive and new clas-
sification of SSRIs/SNRIs withdrawal phenomena was out-
lined and specific diagnostic criteria were proposed9, they al-
low to formulate the diagnosis of three different syndromes:
new symptoms, rebound, persistent post-withdrawal disor-
ders9 (Table 1). The prevalence of these syndromes is not
known at the moment, due to their very recent definition and
a lack of diagnostic tools. 
METHODS
Instrument
The Diagnostic clinical Interview for Drug Withdrawal 1 - New
Symptoms of SSRI and SNRI, identified with the acronym DID-
W1, is a brief semi-structured clinical interview which allows the
diagnosis of withdrawal of SSRI or SNRI according to Chouinard
& Chouinard9. It is conducted as a clinical interview by a proper-
ly trained clinician and is divided in five modules:
• the first module (named DID-W1-PD) includes 13 questions
collecting socio-demographic (e.g., date of birth, sex, civil status,
education) or clinical information (i.e., current psychiatric dis-
order, current psychotropic medication use);
• the second module (named DID-W1-SQ) includes screening
questions on the lifetime use of SSRI/SNRI (2 general ques-
tions and 4 questions for each SSRI/SNRI used);
• the third module (named DID-W1-WS1) allows to formulate
the diagnosis of current as well as lifetime new symptoms (26
questions in section a, 27 questions in section b);
• the fourth module (named DID-W1-WS2) allows to formulate
the diagnosis of current as well as lifetime rebound (14 ques-
tions in section a, 15 questions in section b);
• the fifth module (named DID-W1-WS3) allows to formulate the
diagnosis of current as well as lifetime persistent post-withdraw-
al disorders (12 questions in section a, 13 questions in section b). 
Table 1. Withdrawal syndromes according to Chouinard &
Chouinard’s criteria9: new symptoms, rebound, persistent post-
withdrawal disorders.
New symptoms Symptoms not
present before the
beginning of the
SSRI/SNRI
treatment and before
reduction or
discontinuation of
the drug 
• short-lasting 
• reversible 
Unspecific symptoms:
nausea, headaches,
tremor, sleep
disturbances, decreased
concentration, anxiety,
irritability,
agitation/aggression,
depression/dysphoria 
Specific serotonin-related
symptoms: flu-like (e.g.,
flu), cardiovascular 
(e.g., tachycardia),
gastrointestinal 
(e.g., diarrhea),
neuromuscular 
(e.g., myoclonus),
sensory (e.g., electric
shock sensations),
cognitive 
(e.g., confusion), 
sexual (e.g., premature
ejaculation)
Rebound The return of
symptoms which
were present before
the beginning of the
SSRI/SNRI
treatment but not
present before
reduction or
discontinuation of
the drug
• more intense than
before treatment
• rapid
• transient
• reversible
• may be associated to
the psychological
belief of the need of
the drug
• improve rapidly after
reintroduction of the
drug
Persistent 
post-withdrawal 
disorders
The return of
symptoms which
were present before
the beginning of the
SSRI/SNRI
treatment but were
not present before
reduction or
discontinuation of
the drug or of the
return of the original
illness with additional
symptoms (e.g.,
melancholic features
for depression) or
appearance of
symptoms related to
emerging new mental
disorders
• persist longer than 6
weeks after dose
reduction or drug
discontinuation
• have greater intensity
than before treatment
• partially or totally
reversible
• respond partially or
totally to
reintroduction of
discontinued drug
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We designed the DID-W1, the first diagnostic interview
for identifying and differentiating drug withdrawal. It was
based on the new diagnostic criteria proposed by Chouinard
& Chouinard9 taking as model the withdrawal syndromes as-
sociated with all psychotropic drugs including narcotics, hyp-
notics, anxiolytics, and drugs given in medicine to treat for
example high blood pressure25. This semi-structured clinical
interview aims at formulating the diagnosis of new symp-
toms, rebound, and persistent postwithdrawal disorders ac-
cording to the diagnostic criteria by Chouinard &
Chouinard9. This is the first study testing the psychometric
properties of the DID-W1, inter-rater reliability results are
here presented.
The DID-W1: inter-rater reliability
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Modules DID-W1-WS1, DID-W1-WS2, DID-W1-WS3 in-
clude two sections each (section a, section b) which allow to for-
mulate the current (section a) and the lifetime (section b) diagno-
sis of each disorder. Table 2 reports the first question of module
DID-W1-WS1 section as an example. 
Each section of modules DID-W1-WS1, DID-W1-WS2, DID-
W1-WS3 is structured as follows: 
• the first column (named “CURRENT/LIFETIME name of the
syndrome”) suggests the clinical interviewer the question to
formulate;
• the second column (named “DIAGNOSTIC CRITERIA)
(CHOUINARD AND CHOUINARD, 2015)”) reports the spe-
cific diagnostic criterion according to Chouinard & Chouinard9
which can be investigated with the question proposed in the
first column;
• the third column (named “ANSWER”) is the space where the
clinical interviewer reports the answer;
• the fourth column (named “INSTRUCTION FOR THE IN-
TERVIEWER”) describes the instruction which must be fol-
lowed by the clinical interviewer to conduct the interview.
The rater answers YES/NO. The diagnostic algorithm produces
the final diagnoses. At the end of each section a and b, a diagnos-
tic box is provided where the clinical interviewer ticks whether the
diagnostic criteria were satisfied or not. 
The items of the DID-W1 were derived from well-known and
validated diagnostic interviews and scales: the Structured Clinical
Interview for DSM-5, Clinician Version, SCID-5 -CV26; the Mini
International Neuropsychiatric Interview (MINI) 7.0.227; the Clin-
ical Interview for Depression28; the Richmond Agitation-Sedation
Scale29; the Beck Depression Inventory-II30,31; the Extrapyramidal
Symptom Rating Scale31; the Positive and Negative Syndrome
Scale32; the Somatic Symptom Scale-8 (SSS-8)33; the State Trait
Anxiety Inventory – Form Y34; the Psychosocial Index35,36.
Data collection
Seventeen consecutive self-referred outpatients with a history
of SSRI or SNRI reduction or discontinuation were assessed by
2 clinicians (1 psychiatrist, 1 clinical psychologist) independently
at different times during the same day. This was an adequate sam-
ple size for the purpose of validating the interview37. All patients
were studied at the Department of Health Sciences of the Uni-
versity of Florence. The mean age was 43.18 years (SD=11.21
years, range 26-63 years), they were 8 males and 9 females. The
patients had received the antidepressants to treat (diagnoses for-
mulated via the SCID-5 -CV)26: major depressive episode (n=5;
29.41%), major depressive disorder (n=3; 17.65%), panic disor-
der (n=3; 17.64%), panic disorder and agoraphobia (n=3;
17.64%), panic disorder and major depressive episode (n=1;
5.88%), obsessive-compulsive disorder (n=1; 5.88%), schizoaffec-
tive disorder (n=1; 5.88%). The patients had been treated with
paroxetine (n=6; 35.29%), sertraline (n=5; 29.41%), citalopram
(n=2; 11.76%), escitalopram (n=2; 11.76%), fluvoxamine (n=1;
5.89%), venlafaxine (n=1; 5.89%).
Validation design and statistical methods
The DID-W1 was tested as to the inter-rater agreement re-
quirement. It was administered by 2 raters independently assess-
ing the same patient in different times of the same day. This is the
most customary way of assessing observer variability that may
arise from differences in input, procedure, or users. 
Percent agreement and Cohen’s kappa were used to measure
inter-rater reliability. Percent agreement is directly interpreted as
the percent of data that are correct. Cohen’s kappa (κ), a robust
statistic for inter-rater testing, is a form of correlation coefficient
which cannot be directly interpreted, but a squared correlation co-
efficient, called the coefficient of determination is directly inter-
pretable38. Similar to correlation coefficients, kappa can range
from −1 to +1, where 0 represents the amount of agreement that
can be expected from random chance, and 1 represents perfect
agreement between the raters. Cohen suggested the kappa result
be interpreted as follows: ≤0 no agreement; 0.01-0.20 none to
slight; 0.21-0.40 fair; 0.41-0.60 moderate; 0.61-0.80 substantial;
0.81-1.00 almost perfect agreement39.
Table 2. First row of module DID-W1-WS1, section a.
Current new 
withdrawal 
symptoms
Diagnostic 
criteria9
Answer Instruction for
the interviewer
After the last dose
reduction or
discontinuation of
(name of the
drug), has there
been a period of
time when you
have had
symptoms that
you did not have
before, except in
previous attempt
to reduce or
discontinue a
psychotropic
medication? 
If yes would you
relate them to
dose reduction or
discontinuation of
(name of the
drug)?
(B) One or
more of the
following
symptoms:
nausea,
headaches,
tremor, sleep
disturbances,
decreased
concentration,
anxiety,
irritability,
agitation,
aggression,
depression, or
dysphoria
ø Yes
ø No
if yes to both
questions, code
yes
if no, code no in
the box at the
end of section
1A and go to
section 1B
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RESULTS
The percent agreement for the whole interview was
97.06%, the Cohen’s kappa was 0.85 (SE=0.083) with a 95%
CI of 0.61-1.08, the squared correlation coefficient was 0.72.
Inter-rater concordance was excellent. Table 3 reports the
percent agreement, the Cohen’s kappa with 95% CI, and the
squared correlation coefficient for each diagnosis. 
DISCUSSION
A kappa value above 0.80 indicates excellent inter-rater
agreement and suggests that the DID-W1 is a reliable
method for diagnostic evaluation in SSRI/SNRI withdrawal
syndromes. 
This is the first tool designed to identify and classify the
various clinical manifestations that are associated with SSRI
and SNRI discontinuation, according to Chouinard &
Chouinard’s9 diagnostic criteria. The most widely used
method for assessing such phenomena has been for a long
time the Discontinuation Emergence Signs and Symptoms
(DESS)40, a checklist of signs and symptoms of withdrawal
with no diagnostic purposes, even though the patients may be
classified as experiencing a withdrawal syndrome if the num-
ber of DESS checklist events increased by four or more dur-
ing the discontinuation period.
The DID-W1 is an interview which may have a number of
important clinical and research implications. First, it is a tool
for identifying and differentiating the clinical phenomena
that may occur upon SSRI and SNRI discontinuation. Not
surprisingly, there is a wide variation (between 14 and 78%)
on the incidence of withdrawal symptoms after dose reduc-
tion, discontinuation, or switch of SSRIs or SNRI9,41. It may
depend on drug differences and on the samples that are stud-
ied, but also on the lack of suitable diagnostic instruments.
Second, it may help differentiating withdrawal phenomena
from relapse9,42. In clinical practice, lack of appraisal of with-
drawal phenomena may lead to inappropriate clinical deci-
sions, such as unnecessary re-institution of drug treatment. In
research, it may allow to differentiate between withdrawal
phenomena and relapse after antidepressant discontinuation,
which would otherwise be impossible to discern43; it may yield
a full assessment of side effects of antidepressant drugs41; it
may lead to a correct identification of distress and use of an-
tidepressants in epidemiological studies44. Finally, psychiatric
symptoms in clinical practice may also be a consequence of
previous pharmacological treatments, the so called iatrogenic
comorbidity, that would require removal of the drug but is
more often interpreted as a justification for new treatment11.
For instance, much of the refractoriness to treatment of anx-
ious depression may be actually due to post-withdrawal dis-
orders that are secondary to the use of antidepressant drugs
in anxiety disorders45. Such research efforts pertain to the do-
mains of clinical pharmacopsychology, an emerging area that
is concerned with the subtle psychological modification in-
duced by psychotropic and medical drugs, with particular ref-
erence to behavioral toxicity and iatrogenic comorbidity46,47.
It is hoped that the DID-W1 will encourage studies on
this topic and may lead to a refinement of patients’ assess-
ment, as well as treatment, in clinical settings. There is how-
ever the need for other reliability studies on the DID-W1
such as comparisons with the DESS as well as construct va-
lidity studies. There is also need of similar semi-structured in-
terviews to be produced for classifying withdrawal syndrome
related to other drugs, such as antipsychotics25. 
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